Abstract
Background Mean Platelet Volume (MPV) has been proposed as a potential predictor of increased mortality risk at 6 months among Chinese patients with heart failure (HF). However, the current evidence supporting this association is limited.
Methods This study aimed to investigate the relationship between MPV and HF short-term survival status. The data was obtained from a publicly accessible HF database in Zigong, Sichuan, and included information on 2008 Chinese patients. Baseline MPV was considered as the exposure while HF short-term survival status was the outcome. Two models, a binary logistic regression model and a two-piecewise linear model, were used to analyze the data.
Results The study revealed a U-shaped relationship between MPV and all-cause mortality in HF patients. When MPV levels were less than 9.8, every unit increase in MPV was associated with a 91% reduction (RR: 0.09; 95% CI: 0.03-0.24; P=0.0001) in the risk of death over the next six months. In contrast, at MPV levels above 9.8, each unit increase in MPV was linked to a 27% increase (RR: 1.27; 95% CI: 1.01-1.61; P=0.0434) in the probability of dying within the same period. Stratification by obesity status revealed no significant association between MPV and death in the obese population, while the same U-shaped association was observed among non-obese participants.
Conclusion The present study provides evidence of a U-shaped association between MPV and short-term survival in Chinese patients with heart failure. These findings suggest that MPV may serve as a potential prognostic marker for HF. However, further studies are needed to validate these results and to explore the underlying mechanisms of this association. The observed U-shaped association did not apply to obese patients, suggesting that the effect of MPV on mortality risk in HF patients may be influenced by body weight.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N
Funding Statement
No
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Fourth People's Hospital of Zigong
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No
